[8-K] Harmony Biosciences Holdings, Inc. Reports Material Event

Rhea-AI Filing Summary

Phoenix Motor Inc. (PEV) filed a Form 8-K reporting the resignation of Chief Financial Officer Michael Yung, effective 2 Aug 2025. The company states Mr. Yung left for personal reasons and had no disagreements regarding the firm’s operations or accounting practices.

CEO Denton Peng will serve as interim principal financial and accounting officer while the Board undertakes an internal and external search for a permanent replacement. No additional financial results or business updates were included.

The filing also notes that trading of Phoenix Motor’s common stock was suspended on Nasdaq on 15 Apr 2025 and shares now quote on the OTC Pink under the symbol PEVMD.

Positive

• Board has committed to a formal search for an experienced CFO, signalling intent to restore financial leadership stability.

Negative

• CFO Michael Yung’s resignation removes the company’s top financial officer with immediate effect.
• CEO assuming interim CFO role concentrates key management duties, potentially stressing internal controls.

Insights

Corporate Governance Expert

TL;DR: Sudden CFO exit heightens governance risk; interim CEO dual-hat may worry investors.

The unexpected resignation of the CFO at a micro-cap EV maker already delisted from Nasdaq compounds oversight concerns. Even though the company claims no accounting disagreements, losing a key financial steward without an immediate successor can disrupt reporting processes and lender confidence. CEO Denton Peng’s assumption of CFO duties creates high key-person concentration and potential internal control strain until a qualified finance chief is hired.

Financial Analyst

TL;DR: Leadership gap is notable but no direct financial data provided; impact modest near term.

While management turnover is negative, the filing lacks earnings or liquidity metrics, limiting quantitative assessment. Investors will monitor how quickly the board secures an experienced CFO and whether the change affects audit timelines or capital-raising plans. Given shares already trade OTC, market reaction may be muted unless follow-up disclosures reveal operational fallout.

0001802665false00018026652025-08-052025-08-05

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

​

Date of report (Date of earliest event reported): August 5, 2025

​

HARMONY BIOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

​

​	​	​
Delaware	001-39450	82-2279923
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

​

630 W. Germantown Pike, Suite 215

Plymouth Meeting, PA 19462

(Address of principal executive offices) (Zip Code)

(484) 539-9800

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​	​	​	​	​
​		Trading		Name of each exchange
Title of each class	​	Symbol(s)	​	on which registered
Common Stock, $0.00001 par value per share	​	HRMY	​	The Nasdaq Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 2.02.    Results of Operations and Financial Condition.

On August 5, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On August 5, 2025, the Company posted an investor presentation to its website at ttps://ir.harmonybiosciences.com (the “Investor Presentation”). A copy of the Investor Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others.

​

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Investor Presentation speaks only as of the date of this Current Report on Form 8-K. The Company undertakes no duty or obligation to publicly update or revise the information contained in the Investor Presentation, although it may do so from time to time. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. In addition, the exhibit furnished herewith contains statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in such exhibit. By furnishing the information contained in the Investor Presentation, the Company makes no admission as to the materiality of any information in the Investor Presentation that is required to be disclosed solely by reason of Regulation FD.

​

This Current Report on Form 8-K and its contents (including Exhibits 99.1 and 99.2) are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Note Regarding Forward-Looking Statements

Certain statements in this Current Report on Form 8-K constitute “forward-looking statements” within the meaning of the federal securities laws. These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein including the risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (“SEC,”) on February 25, 2025, as well as other factors described from time to time in the Company’s filings with the SEC. Such forward-looking statements are made only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law. If it does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

​

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

​	​	​
Exhibit		​
No.	​	Description
​	​	​
99.1*	​	Press release issued by the Company, dated August 5, 2025.
​	​	​
99.2*	​	Investor Presentation dated August 5, 2025.
​	​	​
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

* This Exhibit is furnished herewith and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that Harmony Biosciences Holdings, Inc. specifically incorporates it by reference.

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	HARMONY BIOSCIENCES HOLDINGS, INC.
​	​
Date: August 5, 2025	By:	/s/ Sandip Kapadia
​	​	Sandip Kapadia
​	​	Chief Financial Officer and Chief Administrative Officer

​

​

​

​